Inherited epidermolysis bullosa: Recent basic and clinical advances

Current Opinion in Pediatrics

Volumn 22, Issue 4, 2010, Pages 453-458

  Fine, Jo David ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

animal model; clinical; epidermolysis bullosa; extracutaneous; fibroblast; gene therapy; stem cell therapy; type VII collagen

Indexed keywords

AMITRIPTYLINE; CARNITINE; COLLAGEN TYPE 7; FIBRONECTIN; IMMUNOGLOBULIN A; PLECTIN; RECOMBINANT PROTEIN; SELENIUM;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLISTER; CARCINOGENESIS; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DEATH; DEPRESSION; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG TOXICITY; EPIDERMOLYSIS BULLOSA HEREDITARIA; ESOPHAGUS STRICTURE; EVIDENCE BASED PRACTICE; EXPERIMENTAL ANIMAL; EXTRAOCULAR MUSCLE; FAMILY CONFLICT; FIBROBLAST; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE REPLACEMENT THERAPY; GENOTYPE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IRON OVERLOAD; KIDNEY FAILURE; LARYNGOTRACHEAL STENOSIS; LARYNX STENOSIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOSYNDACTYLY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCAR FORMATION; SEVERE COMBINED IMMUNODEFICIENCY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; SUICIDAL IDEATION; SYNDACTYLY; TOOTH DISEASE; UROGENITAL TRACT DISEASE; WOUND CARE; EPIDERMOLYSIS BULLOSA; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENETICS; PROGNOSIS;

EPIDERMOLYSIS BULLOSA; GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; GENOTYPE; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 77955229189     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833bb74f     Document Type: Review

References (61)

1. Fine J-D, Hintner H. Life with epidermolysis bullosa: etiology, diagnosis, and multidisciplinary care and therapy. Wien New York: Springer Verlag GmbH; 2009.
2. Fine JD, Mellerio J. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: Part II. Other organs. J Am Acad Dermatol 2009; 61:387-402.
3. Fine JD, Mellerio J. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: Part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61:367-384.
4. Jonkman MF, Pasmooij AM. Revertant mosaicism-patchwork in the skin. N Engl J Med 2009; 360:1680-1682.
5. Koebner H. Hereditare anlage zur blasenbildung (epidermolysis bullosa hereditaria). Dtsch Med Wochenschr 1886; 12:21-22.
6. Pearson RW. Studies on the pathogenesis of epidermolysis bullosa. J Invest Dermatol 1962; 39:551-575.
7. Fine J-D, Eady RAJ, Bauer JA, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931-950.
8. Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010; 130:1551-1557.
9. Almaani N, Lui L, Dopping-Hepenstal PJ, et al. Autosomal dominant junctional epidermolysis bullosa. Br J Dermatol 2009; 160:1094-1097.
10. Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol 2009; 160:1057-1065.
11. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol 2009; 161:1323-1330.
12. Fine J-D, Johnson LB, Weiner M, et al. Eye involvement in inherited epidermolysis bullosa (EB): experience of the National EB Registry. Am J Ophthalmol 2004; 138:254-262.
13. Fine J-D, Johnson LB, Weiner M, et al. Pseudosyndactyly and musculoskeletal deformities in inherited epidermolysis bullosa (EB): experience of the National EB Registry, 1986-2002. J Hand Surg (British and European Volume) 2005; 30B:14-22.
14. Fine J-D, Johnson LB, Weiner M, Suchindran C. Tracheolaryngeal complications of inherited epidermolysis bullosa. Laryngoscope 2007; 117:1652-1660.
15. Fine J-D, Johnson LB, Weiner M, Suchindran C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National EB Registry. J Pediatr Gastroenterol Nutr 2008; 46:147-158.
16. Fine J-D, Johnson LB, Weiner M, et al. Genitourinary complications of inherited epidermolysis bullosa (EB): experience of the National EB Registry and review of the literature. J Urol 2004; 172:2040-2044. (Pubitemid 39363124)
17. Fine J-D, Johnson LB, Weiner M, et al. Inherited epidermolysis bullosa (EB) and the risk of death from renal disease: experience of the National EB Registry. Am J Kidney Dis 2004; 44:651-660. (Pubitemid 39237609)
18. Fine J-D, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status, and family size. Br J Dermatol 2005; 152:1009-1014.
19. Fine J-D, Hall M, Weiner M, et al. The risk of cardiomyopathy in inherited epidermolysis bullosa. Br J Dermatol 2008; 159:677-682.
20. Fine J-D, Johnson LB, Weiner M, et al. Inherited epidermolysis bullosa (EB) and the risk of life-threatening skin-derived cancers: experience of the National EB Registry, 1986-2006. J Am Acad Dermatol 2009; 60:203-211.
21. Fine J-D, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr 2008; 152:276-280.
22. Kawasaki Y, Isome M, Takano K, et al. IgA nephropathy in a patient with dominant dystrophic epidermolysis bullosa. Tohoku J Exp Med 2008; 214:297-301.
23. Bolling MC, Pas HH, de Visser M, et al. PLEC1 mutations underlie adult-onset dilated cardiomyopathy in epidermolysis bullosa simplex with muscular dystrophy. J Invest Dermatol 2010; 130:1178-1181.
24. Taibjee SM, Ramani P, Brown R, Moss C. Lethal cardiomyopathy in epidermolysis bullosa associated with amitryptiline. Arch Dis Child 2005; 90:871-872.
25. Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl. Int J Dermatol 2009; 48:731-733.
26. Fine J-D. Possible role of sentinal node biopsy in the management of squamous cell carcinomas in inherited epidermolysis bullosa. Arch Dermatol 2004; 140:1012-1013.
27. Perez-Naranjo L, Herrera-Saval A, Garcia-Bravo B, et al. Sentinel lymph node biopsy in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. Arch Dermatol 2005; 141:110-111.
28. Rokunohe A, Nakano H, Aizu T, et al. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa. J Dermatol 2008; 35:336-340.
29. Fine J-D, Johnson LB, Weiner M, et al. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004; 50:563-571.
30. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219:80-83.
31. Igoucheva O, Kelly A, Uitto J, Alexeev V. Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro. J Invest Dermatol 2008; 128:1476-1486.
32. Di Nunzio F, Maruggi G, Ferrari S, et al. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol Ther 2008; 16:1977-1985.
33. Fritsch A, Spassov S, Elfert S, et al. Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII. J Biol Chem 2009; 284:30248-30256.
34. Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 2008; 118:1669-1679.
35. Remington J, Wang X, Hou Y, et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009; 17:26-33.
36. Kern JS, Loeckermann S, Fritsch A, et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors longterm skin integrity. Mol Ther 2009; 17:1605-1615.
37. Woodley DT, Remington J, Huang Y, et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 2007; 15:628-635.
38. Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004; 10:693-695.
39. Chino T, Tamai K, Yamazaki T, et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008; 173:803-814.
40. Tolar J, Ishida-Yamamoto A, Riddle M, et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009; 113:1167-1174.
41. Arin MJ, Roop DR. Inducible mouse models for inherited skin diseases: implications for skin gene therapy. Cells Tissues Organs 2004; 177:160-168.
42. Cao T, Longley MA, Wang XJ, Roop DR. An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol 2001; 152:651-656.
43. Roth W, Reuter U, Wohlenberg C, et al. Cytokines as genetic modifiers in K5-/- mice and in human epidermolysis bullosa simplex. Hum Mutat 2009; 30:832-841.
44. Bauer EA. Recessive dystrophic epidermolysis bullosa: evidence for altered collagenase in fibroblast cultures. Proc Natl Acad Sci U S A 1977; 74:4646-4650.
45. Bauer EA, Cooper TW, Tucker DR, Esterly NB. Phenytoin therapy of recessive dystrophic epidermolysis bullosa. Clinical trial and proposed mechanism of action on collagenase. N Engl J Med 1980; 303:776-781.
46. Titeux M, Pendaries V, Tonasso L, et al. A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. Hum Mutat 2008; 29:267-276.
47. Mallipeddi R, Wessagowit V, South AP, et al. Reduced expression of insulinlike growth factor-binding protein-3 (IGFBP-3) in squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2004; 122:1302-1309.
48. Arbiser JL, Fan CY, Su X, et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 2004; 123:788-790.
49. Martins VL, Vyas JJ, Chen M, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci 2009; 122 (Pt 11):1788-1799.
50. Ortiz-Urda S, Garcia J, Green CL, et al. Type VII collagen is required for Rasdriven human epidermal tumorigenesis. Science 2005; 307:1773-1776.
51. Pourreyron C, Cox G, Mao X, et al. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol 2007; 127:2438-2444.
52. Rodeck U, Uitto J. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis. J Invest Dermatol 2007; 127:2295-2296.
53. Pellegrini G, Rama P, Mavilio F, De Luca M. Epithelial stem cells in corneal regeneration and epidermal gene therapy. J Pathol 2009; 217:217-228.
54. Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128:2179-2189.
55. Matsumoto Y, Dogru M, Tsubota K. Ocular surface findings in Hallopeau-Siemens subtype of dystrophic epidermolysis bullosa: report of a case and literature review. Cornea 2005; 24:474-479.
56. Buonocore SD, Ariyan S. Cadaveric allograft for wound closure after resection of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a report of 32 resections and repairs in 2 patients. Ann Plast Surg 2009; 63:297-299.
57. Betsi EE, Kalbermatten DF, Raffoul W. Surgical management of dystrophic epidermolysis bullosa with autologous composite cultured skin grafts. J Hand Surg Eur Vol 2009; 34:398-399.
58. Hasegawa T, Mizoguchi M, Haruna K, et al. Amnia for intractable skin ulcers with recessive dystrophic epidermolysis bullosa: report of three cases. J Dermatol 2007; 34:328-332.
59. Jutkiewicz J, Noszczyk BH, Wrobel M. The use of biobrane for hand surgery in epidermolysis bullosa. J Plast Reconstr Aesthet Surg 2009. [Epub ahead of print]
60. Hon J. Using honey to heal a chronic wound in a patient with epidermolysis bullosa. Br J Nurs 2005; 14:S4-S12.
61. Larrazabal-Moron C, Boronat-Lopez A, Penarrocha-Diago M. Oral rehabilitation with bone graft and simultaneous dental implants in a patient with epidermolysis bullosa: a clinical case report. J Oral Maxillofac Surg 2009; 67:1499-1502.